Eli Lilly's obesity drug retatrutide showed significant weight loss in patients with heart disease but did not conclusively reduce cardiovascular risks, raising questions about its long-term benefits. Meanwhile, a Medicare pilot program has seen high uptake for injectable GLP-1 drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Foundayo/Zepbound, challenging initial expectations that patients would prefer oral medications due to the convenience of injections.
This development matters as it highlights ongoing uncertainties in obesity drug efficacy and patient preferences, influencing future clinical trials and market strategies.
Read the full article at STAT Pharma
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.





